59
Participants
Start Date
June 30, 2010
Primary Completion Date
May 31, 2014
Study Completion Date
May 31, 2014
Bendamustine
Starting dose of 70 mg/m\^2 by vein on Days 1 and 2 of a 28 day cycle
Bevacizumab
10 mg/kg by vein on Days 1 \& 15 of every 28 day cycle
UT MD Anderson Cancer Center, Houston
Collaborators (1)
Cephalon
INDUSTRY
National Comprehensive Cancer Network
NETWORK
M.D. Anderson Cancer Center
OTHER